Clinical Trial Update: Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL) [Phase 2]

View source ↗

Summary

SWOG's Phase 2 trial evaluating adding avelumab to gemcitabine and carboplatin before surgery in cisplatin-ineligible muscle-invasive urinary tract cancers was …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer
• Urothelial Carcinoma of the Renal Pelvis
• Urothelial Carcinoma of the Ureter

Drugs mentioned

• BAVENCIO (AVELUMAB)
• CARBOPLATIN (Carboplatin)
• Gemzar (gemcitabine)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2024-12-30